Jump to content

SCLC: Lurbinectedin vs Topotecan - 2nd-line


MyWifeSCLC

Recommended Posts

I completed my layman's comparison of Lubinectedin vs Topotecan this morning. I compared data from the recent Lurbinectedin phase II trial and a 2015 Scientific Reports pooled systematic review of Topotecan [Scientific Reports 5:15437 DOI: 10.1038/srep15437]. In my untrained opinion, Lurbinectedin beats Topotecan easily for 2nd-line treatment! My comparison data is shown below. Please research definitions of acronyms in the NCI dictionary. Comparison order of numbers will be Lurbinectedin vs Topotecan.

OS 6mos (refractory): 61.9% to 37%

OS 1yr (refractory): 22.9% to 9%

OS 6mos (sensitive): 92.7% to 57%

OS 1yr (sensitive): 59.1% to 27%

DCR (refractory): 61% to 29%

DCR (sensitive): 79% to 42%

PR (refractory): 33.3% to 3%

PR (sensitive): 44.4% to 14%

PD (refractory): 37% to 59%

PD (sensitive): 17.6% to 48%

AE (grade 3/4): 34.3% to 69%

OS (mos): 9.3 to 5.8

PFS (mos): 3.9 to 3.9

ORR: 35.2% to 24%

Refractory vs sensitive is disease recurrence < vs > 3 months after 1st-line treatment. OS is overall survival; DCR is disease control rate; PR is partial response; PD is progressive disease; AE is adverse event; PFS is progression-free survival; and ORR is overall response rate.

An oncologist should be able to explain the comparison and whether it is valid, since the data is not "head-to-head". Let's hope the drug Lurbinectedin becomes available soon.

Steve

 

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.